EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia

Terrence Lo, Han Byul Kang, Carol McNair, Diane Wilson, Jennifer Bizzarri, Brian T. Kalish, Emily W. Y. Tam, Winnie Seto, Erin Chung

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-12 · 46 (12)

DOI: 10.1002/phar.70221 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2026-11-18. Written by Terrence Lo and 8 co-authors. 28 references. The full text is freely available (open access, CC BY-NC 4.0).

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objectives

Recently, dexmedetomidine has replaced opioids for sedation in neonatal intensive care unit (NICU) patients with hypoxic–ischemic encephalopathy (HIE). The study objectives were to describe dosing patterns, evaluate compliance, and compare effectiveness and safety between the original (pre‐implementation) and revised (post‐implementation) in‐house dexmedetomidine dosing guidelines. Study Design This was a retrospective cohort study that included neonates with HIE admitted to a level IV NICU for therapeutic hypothermia comparing two dexmedetomidine dosing regimens: (1) pre‐implementation: starting dose of 0.05 μg/kg/h followed by titration by 0.05 μg/kg/h every 6 h as needed, and (2) post‐implementation: 0.2 μg/kg/h followed by titration by 0.1 μg/kg/h every 30–60 min as needed.

Results

A total of 106 neonates were included: 50 in the pre‐implementation group and 56 in the post‐implementation group. Compliance to post‐implementation formulary recommendations was 69.6% for initial doses, 62.5% for dose increases, and 44.6% for dose decreases. An increased odds of opioid exposure (adjusted odds ratio: 7.13, 95% confidence interval (CI): 1.59–51.5, p = 0.02) and greater proportion of bradycardia (21.4% vs. 4%, p = 0.03) were observed in the post‐implementation group. No significant differences in effectiveness end points or hypotension were observed between groups ( p ≥ 0.05).

Conclusion

Compliance with formulary‐recommended dexmedetomidine dosing was variable and dose decreases were common in the post‐implementation group. The post‐implementation dosing approach was not associated with improved effectiveness outcomes (sedation) but was associated with greater opioid exposure and more bradycardia, supporting the need for further prospective evaluation to determine the optimal dexmedetomidine dosing in neonates undergoing HIE.

Cite

APA

Lo, T., Kang, H. B., McNair, C., Wilson, D., Bizzarri, J., Kalish, B. T., Tam, E. W. Y., Seto, W., & Chung, E. (2026). Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(12). https://doi.org/10.1002/phar.70221

Vancouver

Lo T, Kang HB, McNair C, Wilson D, Bizzarri J, Kalish BT, et al. Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(12). doi:10.1002/phar.70221

BibTeX
@article{Lo2026,
  author = {Lo, Terrence and Kang, Han Byul and McNair, Carol and Wilson, Diane and Bizzarri, Jennifer and Kalish, Brian T. and Tam, Emily W. Y. and Seto, Winnie and Chung, Erin},
  title = {Dexmedetomidine Dosing Evaluation for Sedation in Neonates Undergoing Therapeutic Hypothermia},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {12},
  doi = {10.1002/phar.70221}
}
Start for free →